BeiGene
BGNE
#849
Rank
NZ$38.79 B
Marketcap
$350.21
Share price
-4.40%
Change (1 day)
20.34%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: NZ$38.79 Billion

As of October 2024 BeiGene has a market cap of NZ$38.79 Billion. This makes BeiGene the world's 849th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Marketcap Change
2024NZ$38.79 B23.8%
2023NZ$31.33 B-15.2%
2022NZ$36.95 B-8.18%
2021NZ$40.24 B20.84%
2020NZ$33.30 B118.01%
2019NZ$15.27 B22.94%
2018NZ$12.42 B98.29%
2017NZ$6.26 B260.33%
2016NZ$1.73 B

End of Day market cap according to different sources

On Oct 17th, 2024 the market cap of BeiGene was reported to be:

NZ$38.79 Billion
by Yahoo Finance info icon info icon
NZ$38.79 Billion
by CompaniesMarketCap info icon info icon
NZ$37.16 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
NZ$34.46 M-99.91%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.66 B-95.71%๐Ÿ‡บ๐Ÿ‡ธ USA